Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis
Received 22 March 2018
Accepted for publication 24 July 2018
Published 12 October 2018 Volume 2018:11 Pages 2343—2351
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Katherine Hanlon
Fan Meng, Ke Peng, Jian-Ping Yang, Fu-Hai Ji, Fan Xia, Xiao-Wen Meng
Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Aim: This meta-analysis was performed to evaluate the efficacy and safety of botulinum toxin-A (BTX-A) for the treatment of neuralgia.
Methods: We searched PubMed, EMBASE, and Cochrane databases to identify randomized controlled trials (RCTs) comparing BTX-A treatment with saline for alleviating neuropathic pain. Primary outcome measures were pain scores up to 24 weeks after treatment. Secondary outcomes were hours of sleep, Short Form-36 (SF-36) life quality questionnaire, and adverse events. We used Review Manager 5.3 for the data analyses.
Results: Twelve RCTs were included (n=495). Pain scores in the BTX-A group were significantly lower compared to the saline group at 4 weeks (mean difference [MD] =–1.64, 95% CI [–3.21, –0.07], P=0.04), 12 weeks (MD =–1.49, 95% CI [−2.05, –0.93], P<0.00001), and 24 weeks (MD =–1.61, 95% CI [−2.81, –0.40], P=0.009). There were no significant differences in hours of sleep, SF-36 questionnaire, or the incidence of injection pain or hematoma between the two groups. No serious adverse events associated with BTX-A were noted. Fourteen out of 108 patients (12.9%) with trigeminal neuralgia experienced mild facial asymmetry after the BTX-A treatment.
Conclusion: Based on the current evidence, BTX-A may be an effective and safe option for the treatment of neuralgia. Due to the limited number of patients included in this meta-analysis, more trials are still needed to confirm these results.
Keywords: botulinum toxin, neuralgia, neuropathic pain, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]